home / stock / awkn:cc / awkn:cc news

AWKN:CC News and Press, AWAKN LIFE SCIENCES CORP. From 02/12/24

Stock Information
Company Name: AWAKN LIFE SCIENCES CORP.
Stock Symbol: AWKN:CC
Market: AQNC
Website: awaknlifesciences.com
Menu
AWKN:CC AWKN:CC Quote AWKN:CC Short AWKN:CC News AWKN:CC Articles AWKN:CC Message Board
Get AWKN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
AWKN:CC - Awakn Life Sciences Announces Listing on the Canadian Securities Exchange

Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to...
AWKN:CC - Awakn Life Sciences Announces Conditional Approval of CSE Listing

Toronto, Ontario--(Newsfile Corp. - February 5, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to ...

AWKN:CC - Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers

Awakn Designates Program AWKN-002 for Alcohol Use Disorders in the US Market Toronto, Ontario--(Newsfile Corp. - January 24, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for ad...

AWKN:CC - Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS

Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating Disorders Also Includes Access to Phase 1 Data and Patents Filed in US and Key International Markets Toronto, Ontario--(Newsfile Corp. - December 20, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF...
AWKN:CC - Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001

AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use Disorder Toronto, Ontario--(Newsfile Corp. - November 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a clinical-stage ...

AWKN:CC - Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements

Toronto, Ontario--(Newsfile Corp. - November 10, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today that it has r...

AWKN:CC - Awakn Life Sciences Engages Orphan Insight Ltd. to Advance Market Access, Pricing, and Reimbursement Strategies for AWKN-P001 Targeting Severe Alcohol Use Disorder

Toronto, Ontario--(Newsfile Corp. - October 31, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces it has engaged Orpha...
AWKN:CC - Awakn Life Sciences Completes MDMA Zydis(R) ODT Feasibility Study

Study Confirms MDMA Is Stable on Zydis(R) ODT and Suitable for Pre-Gastric Absorption Toronto, Ontario--(Newsfile Corp. - October 4, 2023) -  Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical stage biotechnology company developing therapeutics to treat ad...

AWKN:CC - Awakn Life Sciences Provides Corporate Update

Announces Closing of Third Tranche of Private Placement Toronto, Ontario--(Newsfile Corp. - September 14, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on...

AWKN:CC - Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001

AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use Disorder Toronto, Ontario--(Newsfile Corp. - September 6, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biote...
Previous 10 Next 10